AQR Capital Management LLC Lowers Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

AQR Capital Management LLC decreased its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 66.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,781 shares of the biotechnology company’s stock after selling 70,273 shares during the period. AQR Capital Management LLC owned about 0.06% of Aldeyra Therapeutics worth $115,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ALDX. Kingswood Wealth Advisors LLC purchased a new stake in Aldeyra Therapeutics during the first quarter worth about $49,000. Acadian Asset Management LLC boosted its holdings in Aldeyra Therapeutics by 106.3% during the first quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock worth $1,478,000 after buying an additional 233,169 shares in the last quarter. Diversified Trust Co purchased a new stake in Aldeyra Therapeutics during the second quarter worth about $41,000. Los Angeles Capital Management LLC boosted its holdings in Aldeyra Therapeutics by 240.9% during the first quarter. Los Angeles Capital Management LLC now owns 380,773 shares of the biotechnology company’s stock worth $1,245,000 after buying an additional 269,061 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Aldeyra Therapeutics during the first quarter worth about $585,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Trading Up 2.7 %

Shares of ALDX opened at $5.70 on Friday. The stock has a market cap of $338.66 million, a P/E ratio of -11.18 and a beta of 1.44. The company has a 50-day moving average of $5.53 and a two-hundred day moving average of $4.44. Aldeyra Therapeutics, Inc has a 12-month low of $1.46 and a 12-month high of $6.55.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.